BioPharm Insight Adds New Investigative Journalists to Increase Coverage of Global Healthcare and Medical Device Sectors

Share Article

Niccola Perez and Kotaro Yoshida join Infinata’s premier forward-looking intelligence editorial team in New York City.

BioPharm Insight, Infinata, Inc.’s cornerstone biopharma intelligence solution, announces two new additions to its prestigious investigative journalist team to expand coverage in the global healthcare and medical device sectors. BioPharm Insight is an independent intelligence subscription service based in New York City, London and Hong Kong. The editorial team focuses on breaking news 6-12 months in advance of market-moving events in the healthcare industry, through interviews with CEOs, key opinion leaders, researchers, clinicians, industry sources and more. Both of the new journalists bring significant scientific experience and biopharma understanding to their roles.

Niccola Perez joins the team as a healthcare reporter primarily covering drug development. She was previously a PhD candidate at the biomedical engineering program at Columbia University and served as Managing Editor and President of the peer-reviewed Columbia Science Review. Ms. Perez has also worked with the Medical Unit at CNN, conducted laboratory research at Institut Pasteur in Paris, and served as an academic associate on several ongoing clinical studies at St. Luke's-Roosevelt Hospital in New York. Additional experience includes qualitative research at a regional office of the World Health Organization in El Salvador and industry R&D with the Adhesives Division of 3M in Northern France.

Kotaro Yoshida joins BioPharm Insight as a dedicated medical device reporter. Mr. Yoshida was most recently a PhD candidate in Immunology at Duke University, focusing primarily on developing cancer vaccines. He has an MS in Biology with specialization in immunotoxicology from New York University, and has been published in numerous journals. He graduated from Johns Hopkins University with a double major in Biology and Mathematics.

Kimberly Ha, Global Editor for BioPharm Insight said, “Ms. Perez and Mr. Yoshida are excellent additions to our reporting team and will help us continue to expand our renowned editorial coverage further into critical healthcare and medical device issues. We are also building a larger reporting team in Asia, to provide our readers with valuable local intelligence on a daily basis.”

About BioPharm Insight

BioPharm Insight is a comprehensive online system profiling global companies, key R&D and management contacts, drug pipelines, M&A and licensing deals, sales forecast and more. This real-time database is supported by proprietary forward-looking intelligence uncovered by a dedicated team of unbiased investigative journalists on a daily basis. To learn more, visit

About Infinata, Inc.

Infinata provides personalized technology solutions to help clients turn information into insight. Featuring exclusive biopharmaceutical intelligence and business development tools such as BioPharm Insight™ and BioPharm Clinical™, Infinata helps biopharma companies, CROs, service providers and financial markets firms understand and become active participants in their global industry. Infinata is a part of mergermarket, a Financial Times Group company. To learn more, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Holly Burke
(781) 619-0131
Email >